Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Given the study did not show a significant difference in fibrosis stage, semaglutide has not yet been FDA approved for NASH
Scientific Evidence So, what does the research actually tell us
Tirzepatide (Zepbound In a 72-week study, people taking tirzepatide lost an average of ): 21% of their body weight
But Zepbound and Wegovy are not the same
Yet studies show that people who achieve up to 20% weight loss on these drugs often regain that weight quickly if they stop treatment
Furthermore, studies have examined these effects in fibroblast and keratinocyte cultures, endothelial and neuronal systems, and preclinical animal models related to wound repair and tissue response
US$ 29.77
US$ 29.35
US$ 29.77
US$ 21.78
